vs
Assertio Holdings, Inc.（ASRT）与AMREP CORP.（AXR）财务数据对比。点击上方公司名可切换其他公司
AMREP CORP.的季度营收约是Assertio Holdings, Inc.的1.1倍（$14.6M vs $13.5M），AMREP CORP.同比增速更快（93.8% vs -57.9%），过去两年AMREP CORP.的营收复合增速更高（-13.6% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
AMREP是一家总部位于美国新泽西州普林斯顿的企业，核心业务涵盖房地产与媒体服务领域。公司前身为美国地产石油公司，于1961年正式成立，在相关行业拥有六十余年的发展运营历史。
ASRT vs AXR — 直观对比
营收规模更大
AXR
是对方的1.1倍
$13.5M
营收增速更快
AXR
高出151.7%
-57.9%
两年增速更快
AXR
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $14.6M |
| 净利润 | — | $3.1M |
| 毛利率 | — | — |
| 营业利润率 | -86.7% | 20.6% |
| 净利率 | — | 21.6% |
| 营收同比 | -57.9% | 93.8% |
| 净利润同比 | — | 338.9% |
| 每股收益（稀释后） | $-4.54 | $0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTAXR
| Q1 26 | — | $14.6M | ||
| Q4 25 | $13.5M | $9.4M | ||
| Q3 25 | $49.5M | $17.9M | ||
| Q2 25 | $29.2M | $11.2M | ||
| Q1 25 | $26.5M | $7.5M | ||
| Q4 24 | $32.2M | $11.9M | ||
| Q3 24 | $29.2M | $19.1M | ||
| Q2 24 | $31.1M | $19.5M |
净利润ASRTAXR
| Q1 26 | — | $3.1M | ||
| Q4 25 | — | $1.2M | ||
| Q3 25 | $11.4M | $4.7M | ||
| Q2 25 | $-16.4M | $3.9M | ||
| Q1 25 | $-13.5M | $717.0K | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | $-2.9M | $4.1M | ||
| Q2 24 | $-3.7M | $4.1M |
营业利润率ASRTAXR
| Q1 26 | — | 20.6% | ||
| Q4 25 | -86.7% | 11.9% | ||
| Q3 25 | 23.2% | 34.4% | ||
| Q2 25 | -27.5% | 31.7% | ||
| Q1 25 | -50.0% | 5.7% | ||
| Q4 24 | -41.9% | 26.4% | ||
| Q3 24 | -10.4% | 26.1% | ||
| Q2 24 | -11.6% | 23.9% |
净利率ASRTAXR
| Q1 26 | — | 21.6% | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 23.1% | 26.3% | ||
| Q2 25 | -56.0% | 34.8% | ||
| Q1 25 | -51.1% | 9.5% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | -10.0% | 21.3% | ||
| Q2 24 | -11.8% | 21.2% |
每股收益（稀释后）ASRTAXR
| Q1 26 | — | $0.58 | ||
| Q4 25 | $-4.54 | $0.22 | ||
| Q3 25 | $0.11 | $0.87 | ||
| Q2 25 | $-0.17 | $0.73 | ||
| Q1 25 | $-0.14 | $0.13 | ||
| Q4 24 | $-3.28 | $0.75 | ||
| Q3 24 | $-0.03 | $0.76 | ||
| Q2 24 | $-0.04 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $50.0M |
| 总债务越低越好 | — | $21.0K |
| 股东权益账面价值 | $94.0M | $139.4M |
| 总资产 | $267.0M | $143.9M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资ASRTAXR
| Q1 26 | — | $50.0M | ||
| Q4 25 | $63.4M | $44.6M | ||
| Q3 25 | $93.4M | $48.9M | ||
| Q2 25 | $98.2M | $39.5M | ||
| Q1 25 | $87.3M | $36.9M | ||
| Q4 24 | $100.1M | $40.1M | ||
| Q3 24 | $88.6M | $40.4M | ||
| Q2 24 | $88.4M | $29.7M |
总债务ASRTAXR
| Q1 26 | — | $21.0K | ||
| Q4 25 | — | $23.0K | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | — | $26.0K | ||
| Q1 25 | — | $29.0K | ||
| Q4 24 | — | $32.0K | ||
| Q3 24 | — | $34.0K | ||
| Q2 24 | — | $35.0K |
股东权益ASRTAXR
| Q1 26 | — | $139.4M | ||
| Q4 25 | $94.0M | $136.0M | ||
| Q3 25 | $105.8M | $134.7M | ||
| Q2 25 | $93.3M | $130.0M | ||
| Q1 25 | $108.5M | $126.0M | ||
| Q4 24 | $121.1M | $125.1M | ||
| Q3 24 | $130.5M | $122.2M | ||
| Q2 24 | $132.2M | $118.0M |
总资产ASRTAXR
| Q1 26 | — | $143.9M | ||
| Q4 25 | $267.0M | $140.1M | ||
| Q3 25 | $319.8M | $140.7M | ||
| Q2 25 | $273.8M | $133.8M | ||
| Q1 25 | $286.4M | $128.9M | ||
| Q4 24 | $284.7M | $129.1M | ||
| Q3 24 | $276.0M | $127.0M | ||
| Q2 24 | $279.4M | $122.8M |
负债/权益比ASRTAXR
| Q1 26 | — | 0.00× | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $5.4M |
| 自由现金流经营现金流 - 资本支出 | — | $5.4M |
| 自由现金流率自由现金流/营收 | — | 37.0% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | — | $20.2M |
8季度趋势，按日历期对齐
经营现金流ASRTAXR
| Q1 26 | — | $5.4M | ||
| Q4 25 | $-30.0M | $-4.3M | ||
| Q3 25 | $-4.8M | $9.5M | ||
| Q2 25 | $19.1M | $10.2M | ||
| Q1 25 | $-12.5M | $-3.2M | ||
| Q4 24 | $11.5M | $-182.0K | ||
| Q3 24 | $-35.0K | $10.7M | ||
| Q2 24 | $7.4M | $10.7M |
自由现金流ASRTAXR
| Q1 26 | — | $5.4M | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $-3.3M | ||
| Q4 24 | — | $-268.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $10.3M |
自由现金流率ASRTAXR
| Q1 26 | — | 37.0% | ||
| Q4 25 | — | -45.9% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 86.4% | ||
| Q1 25 | — | -43.4% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 52.5% |
资本支出强度ASRTAXR
| Q1 26 | — | 0.1% | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | — | 2.3% |
现金转化率ASRTAXR
| Q1 26 | — | 1.72× | ||
| Q4 25 | — | -3.54× | ||
| Q3 25 | -0.42× | 2.03× | ||
| Q2 25 | — | 2.63× | ||
| Q1 25 | — | -4.51× | ||
| Q4 24 | — | -0.05× | ||
| Q3 24 | — | 2.63× | ||
| Q2 24 | — | 2.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
AXR
暂无分部数据
